Cargando…

Lymphocyte-Activation Gene-3 Expression and Prognostic Value in Neoadjuvant-Treated Triple-Negative Breast Cancer

PURPOSE: In this study, we aimed to evaluate lymphocyte-activation gene-3 (LAG-3) expression and its prognostic value in neoadjuvant-treated triple-negative breast cancer (TNBC). METHODS: LAG-3, programmed death-1 (PD-1), programmed death ligand-1 (PD-L1), and CD8(+) tumor-infiltrating lymphocyte (T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yunxuan, Dong, Tieying, Xuan, Qijia, Zhao, Hong, Qin, Ling, Zhang, Qingyuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Breast Cancer Society 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015973/ https://www.ncbi.nlm.nih.gov/pubmed/29963107 http://dx.doi.org/10.4048/jbc.2018.21.2.124

Ejemplares similares

Tumor LDH-A expression and serum LDH status are two metabolic predictors for triple negative breast cancer brain metastasis
por: Dong, Tieying, et al.
Publicado: (2017)

The prognostic and predictive value of the lymphocyte to monocyte ratio in luminal-type breast cancer patients treated with CEF chemotherapy
por: Ji, Hongfei, et al.
Publicado: (2016)

Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy
por: Bai, Yu-Ge, et al.
Publicado: (2020)

Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy
por: Herrero-Vicent, Carmen, et al.
Publicado: (2017)

Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers
por: Ruan, Miao, et al.
Publicado: (2018)

Combination of the preoperative albumin to globulin ratio and neutrophil to lymphocyte ratio as a novel prognostic factor in patients with triple negative breast cancer
por: Xuan, Qijia, et al.
Publicado: (2019)

Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers
por: Tian, Tian, et al.
Publicado: (2016)

Immune Lymphocyte Infiltrate and its Prognostic Value in Triple-Negative Breast Cancer
por: Huertas-Caro, Carlos Alexander, et al.
Publicado: (2022)

Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
por: Ding, Feng, et al.
Publicado: (2022)

CD44(+)/CD24(−) phenotype predicts a poor prognosis in triple-negative breast cancer
por: Wang, Hui, et al.
Publicado: (2017)

Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: da Silva, Jesse Lopes, et al.
Publicado: (2021)

Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
por: Castaneda, Carlos A, et al.
Publicado: (2016)

Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer
por: Cavallone, Luca, et al.
Publicado: (2020)

The Clinicopathologic and Prognostic Value of Altered Chromosome 17 Centromere Copy Number in HER2 Fish Equivocal Breast Carcinomas
por: Ji, Hongfei, et al.
Publicado: (2015)

Prognostic value of tumor-infiltrating B lymphocytes and plasma cells in triple-negative breast cancer
por: Kuroda, Hajime, et al.
Publicado: (2021)

Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients
por: Wang, Ruo-Xi, et al.
Publicado: (2018)

Prognostic values of EDNRB in triple-negative breast cancer
por: Liu, Shaoqing, et al.
Publicado: (2020)

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Tanino, Hirokazu, et al.
Publicado: (2016)

Prognostic Significance of Lymphocyte Infiltrate Localization in Triple-Negative Breast Cancer
por: Čeprnja, Toni, et al.
Publicado: (2022)

CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy
por: Tokunaga, Eriko, et al.
Publicado: (2018)

ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
por: Li, Zhijun, et al.
Publicado: (2023)

Predictive and prognostic values of tumor infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: A meta-analysis
por: Li, Shiqi, et al.
Publicado: (2022)

Predictive value of neutrophil-to-lymphocyte-ratio in neoadjuvant-treated patients with breast cancer
por: von Au, Alexandra, et al.
Publicado: (2022)

BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study
por: Kosaka, Yoshimasa, et al.
Publicado: (2020)

Thrombospondin 2 is a Functional Predictive and Prognostic Biomarker for Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy
por: Lin, Yuxiang, et al.
Publicado: (2022)

Optimized tumour infiltrating lymphocyte assessment for triple negative breast cancer prognostics
por: Balkenhol, Maschenka CA., et al.
Publicado: (2021)

Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis
por: Gao, Guoxuan, et al.
Publicado: (2020)

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer
por: Keam, Bhumsuk, et al.
Publicado: (2007)

Prognostic and predictive value of Ki-67 in triple-negative breast cancer
por: Wang, Wei, et al.
Publicado: (2016)

Circulating immune cell dynamics in patients with triple negative breast cancer treated with neoadjuvant chemotherapy
por: Talamantes, Sarah, et al.
Publicado: (2020)

Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy
por: Ortolan, E., et al.
Publicado: (2021)

Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
por: Radosevic-Robin, Nina, et al.
Publicado: (2021)

Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy
por: Vernaci, Grazia, et al.
Publicado: (2023)

Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2015)

Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials
por: Amos, Keith D., et al.
Publicado: (2012)

Controversial issues in the neoadjuvant treatment of triple-negative breast cancer
por: Fitzpatrick, Amanda, et al.
Publicado: (2019)

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study
por: Shao, Zhiying, et al.
Publicado: (2016)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

Prognostic value and immune landscapes of TERT promoter methylation in triple negative breast cancer
por: Lin, Fei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j96lb9pns16mhrl0iluma8vsqa